Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
|
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [1] Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces
    Hofstetter, Birgit
    Gamsjaeger, Sonja
    Phipps, Roger J.
    Recker, Robert R.
    Ebetino, Frank H.
    Klaushofer, Klaus
    Paschalis, Eleftherios P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (05) : 995 - 1003
  • [2] Effects of 1 Year of Daily Teriparatide Treatment on Iliacal Bone Mineralization Density Distribution (BMDD) in Postmenopausal Osteoporotic Women Previously Treated With Alendronate or Risedronate
    Misof, Barbara M.
    Paschalis, Eleftherios P.
    Blouin, Stephane
    Fratzl-Zelman, Nadja
    Klaushofer, Klaus
    Roschger, Paul
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (11) : 2297 - 2303
  • [3] Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate
    Dobnig, Harald
    Stepan, Jan J.
    Burr, David B.
    Li, Jiliang
    Michalska, Dana
    Sipos, Adrien
    Petto, Helmut
    Fahrleitner-Pammer, Astrid
    Pavo, Imre
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (12) : 1998 - 2006
  • [4] Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate
    Bala, Yohann
    Farlay, Delphine
    Chapurlat, Roland D.
    Boivin, Georges
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (04) : 647 - 655
  • [5] Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    R. A. Wermers
    C. P. Recknor
    F. Cosman
    L. Xie
    E. V. Glass
    J. H. Krege
    Osteoporosis International, 2008, 19 : 1055 - 1065
  • [6] Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Wermers, R. A.
    Recknor, C. P.
    Cosman, F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (07) : 1055 - 1065
  • [7] Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
    Hassler, N.
    Gamsjaeger, S.
    Hofstetter, B.
    Brozek, W.
    Klaushofer, K.
    Paschalis, E. P.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 339 - 352
  • [8] Trabecular bone microarchitecture after alendronate treatment of osteoporotic women
    Recker, R
    Masarachia, P
    Santora, A
    Howard, T
    Chavassieux, P
    Arlot, M
    Rodan, G
    Wehren, L
    Kimmel, D
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 185 - 194
  • [9] Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis
    Kucukalic-Selimovic, Elma
    Valjevac, Amina
    Hadzovic-Dzuvo, Almira
    Skopljak-Beganovic, Amra
    Alimanovic-Alagic, Rubina
    Brkovic, Amera
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2011, 11 (01) : 41 - 45
  • [10] Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
    Ma, Yanfei L.
    Zeng, Qing Q.
    Chiang, Alan Y.
    Burr, David
    Li, Jiliang
    Dobnig, Harald
    Fahrleitner-Pammer, Astrid
    Michalska, Dana
    Marin, Fernando
    Pavo, Imre
    Stepan, Jan J.
    BONE, 2014, 59 : 139 - 147